NRG1 Secreted by Cancer-associated Fibroblasts Contributes to Enzalutamide Resistance in Prostate Cancer Cells

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2024 Nov 18

PMID 39553203

Authors

Chunyu Wang

Hongwen Cao

Peng Sun

Lei Chen

Yigeng Feng

Renjie Gao

Affiliations

Soon will be listed here.

Abstract

While androgen deprivation therapy (ADT) continues to be a fundamental aspect of prostate cancer treatment, the development of castration-resistant prostate cancer (CRPC) emphasizes the necessity for a more profound understanding of the tumor microenvironment (TME). Normal fibroblasts (NFs) and cancer-associated fibroblasts (CAFs) were isolated and characterized from normal control and prostate cancer specimens, respectively. PC3 and DU145 cells, and the corresponding enzalutamide resistant counterparts, PC3-EnzR and DU145-EnzR, were co-cultured with NFs or CAFs to evaluate the effects of TME in driving enzalutamide resistance. Cell viability of prostate cancer cells was examined by MTT assay. The study also utilized recombinant human neuregulin-1 (NRG1) protein and siRNA to modulate NRG1 expression in CAFs. RT-qPCR, Western blot, and ELISA were employed to assess gene and protein expressions related to the NRG1-HER3 signaling pathway and its association with enzalutamide resistance. CAFs significantly promoted cell growth and enzalutamide resistance of PC3-EnzR and DU145-EnzR cells through substantial increased secretion of NRG1 by CAFs. Co-culturing enzalutamide-resistant prostate cancer cells (PC3-EnzR and DU145-EnzR) with CAFs further enhanced enzalutamide resistance, as evidenced by elevated IC50 values. Inhibition of NRG1 in CAFs attenuated their impact on enzalutamide resistance, providing insight into the role of NRG1 in mediating the crosstalk between CAFs and prostate cancer in the context of enzalutamide resistance. This study elucidates the pivotal role of CAF-secreted NRG1 in promoting enzalutamide resistance in prostate cancer, providing valuable insights for developing targeted therapeutic strategies to overcome resistance in advanced prostate cancer.

References

Jena B, Sarkar S, Rout L, Mandal M . The transformation of cancer-associated fibroblasts: Current perspectives on the role of TGF-β in CAF mediated tumor progression and therapeutic resistance. Cancer Lett. 2021; 520:222-232. DOI: 10.1016/j.canlet.2021.08.002. View

Kirby M, Hirst C, Crawford E . Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65(11):1180-92. DOI: 10.1111/j.1742-1241.2011.02799.x. View

Rawla P . Epidemiology of Prostate Cancer. World J Oncol. 2019; 10(2):63-89. PMC: 6497009. DOI: 10.14740/wjon1191. View

Cao H, Wang D, Gao R, Feng Y, Chen L . Qi Ling decreases paclitaxel resistance in the human prostate cancer by reversing tumor-associated macrophages function. Aging (Albany NY). 2022; 14(4):1812-1821. PMC: 8908933. DOI: 10.18632/aging.203904. View

Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y . Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2020; 178(2):239-261. DOI: 10.1111/bph.15300. View

Gil V, Miranda S, Riisnaes R, Gurel B, DAmbrosio M, Vasciaveo A . HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Res. 2021; 81(24):6207-6218. PMC: 8932336. DOI: 10.1158/0008-5472.CAN-21-3360. View

Chandrasekar T, Yang J, Gao A, Evans C . Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2016; 4(3):365-80. PMC: 4708226. DOI: 10.3978/j.issn.2223-4683.2015.05.02. View

Wang S, Du P, Cao Y, Ma J, Yang X, Yu Z . Cancer associated fibroblasts secreted exosomal miR-1290 contributes to prostate cancer cell growth and metastasis via targeting GSK3β. Cell Death Discov. 2022; 8(1):371. PMC: 9399109. DOI: 10.1038/s41420-022-01163-6. View

Wu Z, Shi J, Lai C, Li K, Li K, Li Z . Clinicopathological significance and prognostic value of cancer-associated fibroblasts in prostate cancer patients. Urol Oncol. 2021; 39(7):433.e17-433.e23. DOI: 10.1016/j.urolonc.2021.05.004. View

10.

Cookson M, Roth B, Dahm P, Engstrom C, Freedland S, Hussain M . Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013; 190(2):429-38. DOI: 10.1016/j.juro.2013.05.005. View

11.

Barcellos-de-Souza P, Comito G, Pons-Segura C, Taddei M, Gori V, Becherucci V . Mesenchymal Stem Cells are Recruited and Activated into Carcinoma-Associated Fibroblasts by Prostate Cancer Microenvironment-Derived TGF-β1. Stem Cells. 2016; 34(10):2536-2547. DOI: 10.1002/stem.2412. View

12.

Aalinkeel R, Nair B, Reynolds J, Sykes D, Mahajan S, Chadha K . Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol Invest. 2011; 40(5):447-64. DOI: 10.3109/08820139.2011.557795. View

13.

Comito G, Giannoni E, Segura C, Barcellos-de-Souza P, Raspollini M, Baroni G . Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene. 2013; 33(19):2423-31. DOI: 10.1038/onc.2013.191. View

14.

Swami U, McFarland T, Nussenzveig R, Agarwal N . Advanced Prostate Cancer: Treatment Advances and Future Directions. Trends Cancer. 2020; 6(8):702-715. DOI: 10.1016/j.trecan.2020.04.010. View

15.

Wang Y, Wei J, Zhang P, Zhang X, Wang Y, Chen W . Neuregulin-1, a potential therapeutic target for cardiac repair. Front Pharmacol. 2022; 13:945206. PMC: 9471952. DOI: 10.3389/fphar.2022.945206. View

16.

Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L . Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010; 70(17):6945-56. DOI: 10.1158/0008-5472.CAN-10-0785. View

17.

Kelsey R . NRG1 can promote antiandrogen resistance. Nat Rev Urol. 2020; 17(9):486. DOI: 10.1038/s41585-020-0370-4. View

18.

Litwin M, Tan H . The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA. 2017; 317(24):2532-2542. DOI: 10.1001/jama.2017.7248. View

19.

Wang F, Wang C, Xia H, Lin Y, Zhang D, Yin P . Burden of Prostate Cancer in China, 1990-2019: Findings From the 2019 Global Burden of Disease Study. Front Endocrinol (Lausanne). 2022; 13:853623. PMC: 9175004. DOI: 10.3389/fendo.2022.853623. View

20.

Chen L, Cao H, Yu C, Feng Y . Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal. Fundam Clin Pharmacol. 2018; 32(5):548-557. DOI: 10.1111/fcp.12377. View